非小细胞肺癌组织中EphA_2和VEGF的表达及意义

Expression and Clinical Significance of EphA_2 and VEGF in Nonsmall-cell Lung Cancer

目的:探讨EphA2和VEGF在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达情况及与临床病理特征的关系,并研究EphA2阳性表达与VEGF表达的相关性,探讨EphA2阳性表达可能的机制,筛选出能反映肿瘤预后的相关指标。方法:运用免疫组织化学Envision法检测62例NSCLC中EphA2和VEGF的表达情况。结果:EphA2在62例NSCLC的阳性表达率为50.0%(31/62),EphA2的阳性表达率与淋巴结转移、临床分期和5年生存率有关(P<0.05),而与患者吸烟与否、肿瘤的组织学类型和分化程度无关(P>0.05)。VEGF在62例NSCLC的阳性表达率为48.4%(30/62),VEGF的阳性表达与淋巴结转移、临床分期有关(P<0.01),而与患者吸烟与否、肿瘤的组织学类型、分化程度和5年生存率无关(P>0.05)。EphA2与VEGF在NSCLC组织中呈正相关(r=0.648,P<0.01)。结论:EphA2和VEGF阳性表达的NSCLC患者更易发生淋巴结转移,两者可能在NSCLC侵袭转移过程中起协同作用。

Objective： To investigate the expression levels of EphA2 and VEGF in non - small eell lung cancer （NSCLC） and their relationship with the clinicopathological features. And to evaluate the correlation in expression between EphA2 and VEGF. To screen the possible index to predict the prognosis of NSCLC patients. Methods： The expression levels of EphA2 and VEGF were analyzed by envision immunohistochemical method in 62 cases with NSCLC. Results： The expression rate of EphA2 was 50 %. The expression of EphA2 was correlated with lymph node metastasis, clinical stage and 5 year survival rate, and was not related to smoke, histological type or differentiation. The expression rate of VEGF was 48.4 %. Its expression level was sig- nificantly associated with ymph node metastasis and clinical stage, and was not related to smoke, histological type, differentiation and 5 year survival rate. There was a significant correlation in expression between EphA2 and VEGF in NSCLC （r = 0. 648, P 〈 0. 01 ） . Conclusion： Patients with high expression of EphA2 and VEGF are prone to have lymph node metastasis in NSCLC. EphA2 and VEGF may have a synergistic effect on the invasion and metastasis process in NSCLC.